Stručni rad
Photodynamic Therapy Combined with Intravitreal Bevacizumab (Avastin) in Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Ratimir Lazić
Nikica Gabrić
Iva Dekaris
Morena Gavrić
Damir Bosnar
Sažetak
To evaluate photodynamic therapy with verteporfin combined with intravitreal bevacizumab in minimally classic
and occult choroidal neovascularization secondary to age-related macular degeneration. 46 eyes of 46 patients (mean age
74.5) included in this prospective, noncomparative, interventional case series. Median follow-up was 24 weeks (12–36).
Verteporfin photodynamic therapy (PDT) was followed by 0.05 mL (1.25 mg) of bevacizumab injected intravitreally
within 24 hours and again after 6 weeks. Whole procedure was repeated in 3-month intervals in case of leakage. Visual
acuity (VA) improved in majority of patients (baseline VA 1.041 log MAR) by mean increase of 1.45 lines (last follow-up)
(p=0.001). Central foveal thickness (CFT) and total macular volume (TMV) decreased by 53 μm (p=0.03) and 1.04 mm3
(p<0.001) respectively. No serious complications were observed.Combined treatment may improve outcome of monotherapy.
Significant improvement in VA, CFT and TMA was noted in majority of patients and maintained during follow-
up.
Ključne riječi
bevacizumab; photodynamic therapy; choroidal neovascularization
Hrčak ID:
27428
URI
Datum izdavanja:
16.1.2007.
Posjeta: 865 *